Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 23, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain financial performance data for a specific fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial statements.
Material Changes
The filing details specific share purchases made on April 17, 2003, by the SmithKline Beecham Employee Benefit Trust and individual directors:
- Employee Benefit Trust Purchases: The Trust purchased 2,094 shares for the SmithKline Beecham Bonus Investment Plan and 3,284 shares for the GlaxoSmithKline Annual Investment Plan at a price of £12.08 per share.
- Director Purchases (Single Company ISA): Purchases were made at a price of £11.87 per share by Mr. J D Coombe (5 shares), Mrs. G A Coombe (5 shares), and Sir Peter Job (8 shares).
- Director Interests: Directors Dr. J P Garnier and John Coombe hold interests in shares held by the discretionary Employee Benefit Trust.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance report regarding insider trading and director shareholdings.
Key Facts for Investor Verification
- Verify the total number of shares held by directors and the Employee Benefit Trust following the April 17, 2003 transactions.
- Confirm the pricing discrepancy between the Trust purchases (£12.08) and the Single Company ISA purchases (£11.87) on the same date.
- Note that this filing contains no financial performance metrics and should be cross-referenced with the company's Form 20-F for financial data.